Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Amro Elshoury

Hematology & Oncology Indianapolis, IN Medical Doctor

NPI 1417398975 CMS profile 6352301

8326 Naab Rd, Internal Medicine Department, Indianapolis, IN 46260

Open in the dashboard

General payments

$211,801

213 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$202,239 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Amro Elshoury of Indianapolis, IN is reported in the CMS Open Payments database as having received $211,801 across 213 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $202,239 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,464 2
2024 General $107,086 98
2023 General $66,295 73
2022 General $33,388 35
2021 General $456 3
2020 General $2,113 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amro Elshoury
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Amro Elshoury were reported at $2,464. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Amro Elshoury Hematology & Oncology median Middle half National median
2019 $0 $529 $121–$2,516 $163
2020 $2,113 $339 $82–$2,213 $114
2021 $456 $263 $49–$1,965 $132
2022 $33,388 $416 $103–$2,395 $149
2023 $66,295 $542 $125–$2,646 $160
2024 $107,086 $692 $141–$3,008 $164
2025 $2,464 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Blueprint Medicines Corporation $209,105 203 payments
  2. Celgene Corporation $1,663 1 payment
  3. Akebia Therapeutics Inc $450 1 payment
  4. Vertex Pharmaceuticals Incorporated $433 1 payment
  5. BioMarin Pharmaceutical Inc. $46 2 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $33 1 payment
  7. Pfizer Inc. $26 1 payment
  8. Agios Pharmaceuticals, Inc. $24 1 payment
  9. Servier Pharmaceuticals LLC $22 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Honoraria $182,356 69 payments
  2. Travel and Lodging $23,737 87 payments
  3. Food and Beverage $3,132 51 payments
  4. Consulting Fee $2,546 3 payments
  5. Education $30 3 payments
Products named General payments · program years 2020–2025
  1. AYVAKIT Oncology / Rare Diseases $186,380 179 payments
  2. AYVAKIT Oncology / Rare Diseases $2,464 2 payments
  3. INREBIC $1,663 1 payment
  4. VPRIV $33 1 payment
  5. XYNTHA $26 1 payment
  6. BENEFIX $26 1 payment
  7. PYRUKYND $24 1 payment
  8. ONCASPAR $22 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$7,125

Medicare's payments for the services billed

Medicare patients

47

Average age 74

Services billed

261

23 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Cancer 40%
Diabetes 36%
COPD 34%
Ischemic heart disease 32%
Heart failure 28%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AYVAKIT
  • Blueprint Medicines Corporation $86,832
$86,832 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record